-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
SHANGHAI, Nov.
The technology has been developed and completed since 2015.
This invention patent develops a ctDNA-based MRD assessment and dynamic monitoring method for pan-cancer species.
At present, the clinical application of MRD is still in its infancy.
Leadstar independently developed this MRD assessment and dynamic monitoring method based on ctDNA monitoring, which has clinical application value such as minimal residual disease assessment, tumor progression monitoring, and drug efficacy monitoring
The international patent of Linkstar ctDNA monitoring tumor load in blood provides a large amount of multi-cancer type and strong evidence support for the clinical application of ctDNA-based MRD evaluation method, helping clinicians to provide more individualized and precise treatment for patients, enabling China The production and research capabilities in this field have reached the international leading level
Source: Leadstar Bio